Anrukinzumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnrukinzumab

Drug Alias Name安芦珠单抗anrukinzumabum安卢吉珠单抗IMA-638PF-05230917

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionInterleukin-13 inhibitors

TargetsInterleukin-13

Therapy Area/IndicationsAsthmaColitis, Ulcerative

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBulgariaCanadaUnited States +[11]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsAsthmaColitis, Ulcerative

ATC CodeN/A